Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

NCT04757259 · clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Alexion Pharmaceuticals, Inc.